Cambridge, MA, United States of America

Christopher E Rudd


Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 38(Granted Patents)


Location History:

  • Somerville, MA (US) (1989 - 1995)
  • Cambridge, MA (US) (1996)

Company Filing History:


Years Active: 1989-1996

Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Christopher E. Rudd in Immunotherapy**

Introduction

Christopher E. Rudd is a prominent inventor based in Cambridge, MA, recognized for his significant contributions to the field of immunotherapy. With a portfolio of four patents, he focuses on advancing the understanding and modulation of T cell signal transduction, which is crucial for developing new therapeutic strategies against various diseases, including cancer and autoimmune disorders.

Latest Patents

Rudd's latest patents showcase innovative methods to manipulate T cell signaling. One such patent addresses signal transduction via CD28, presenting compositions and methods for blocking T cell signal transduction by introducing a peptide that decreases the association of PI 3-kinase with CD28. Additionally, he has developed methods of amplifying T cell activation through the introduction of modified T cell surface proteins that enhance PI 3-kinase-binding. His work also explores the alteration of interactions between protein tyrosine kinases (PTKs) and T-cell receptors, revealing how these interactions influence T-cell susceptibility to activation and susceptibility to viral infections such as HIV. These inventions have far-reaching implications for cancer research and understanding autoimmune diseases.

Career Highlights

Christopher E. Rudd has established himself at the Dana-Farber Cancer Institute, where he works on groundbreaking research to advance cancer treatment. His innovative work has not only led to the acquisition of patents but has also significantly impacted the field of immunology and cancer biology.

Collaborations

Throughout his career, Rudd has collaborated with notable colleagues, including Stuart F. Schlossman and Prasad V. Kanteti. These partnerships have bolstered research efforts and led to important advancements in understanding T cell biology and its applications in therapy.

Conclusion

As a key figure in immunotherapy, Christopher E. Rudd continues to pave the way for innovations that will enhance our understanding of T cell signaling and its therapeutic implications. His patents represent a vital step towards developing effective treatments for cancer and autoimmune diseases, solidifying his status as an influential inventor in the biomedical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…